Mylan To Wall Street: Forget Patent Cliff, We'll Grow
Five years ago, Mylan (MYL) became the third-largest generic-drug company in the world, catapulted by two acquisitions totaling around $7 billion. But in late October, Watson Pharmaceuticals (WPI) overtook Mylan when it bought Swiss partner Actavis in a deal valued at $5.9 billion. Mylan dropped to No. 4. So Israel's Teva Pharmaceuticals (TEVA) and the Swiss firm Novartis (NVS) remain the top two generic-drug firms worldwide. But Mylan may get
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here